Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland
(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SAR...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2021-11, Vol.10 (22), p.5225 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 22 |
| container_start_page | 5225 |
| container_title | Journal of clinical medicine |
| container_volume | 10 |
| creator | Czarnowska, Agata Kapica-Topczewska, Katarzyna Zajkowska, Olga Adamczyk-Sowa, Monika Kubicka-Bączyk, Katarzyna Niedziela, Natalia Warmus, Paweł Kalinowska-Łyszczarz, Alicja Kania, Karolina Słowik, Agnieszka Wnuk, Marcin Marona, Monika Nowak, Klaudia Bartosik-Psujek, Halina Lech, Beata Perenc, Adam Popiel, Małgorzata Kucharska-Lipowska, Marta Chorąży, Monika Tarasiuk, Joanna Mirończuk, Anna Kochanowicz, Jan Lasek-Bal, Anetta Puz, Przemysław Maciejowska, Katarzyna Wawrzyniak, Sławomir Niezgodzińska-Maciejek, Anna Pokryszko-Dragan, Anna Gruszka, Ewa Budrewicz, Sławomir Białek, Marta Zwiernik, Jacek Michałowska, Anna Nosek, Krzysztof Zwiernik, Beata Lewańczyk, Bożena Brola, Waldemar Kułakowska, Alina |
| description | (1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection; 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms. |
| doi_str_mv | 10.3390/jcm10225225 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8618380</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2604019994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-e3581cdb19e08e1ddc47144486b4137af9f3e5f4c687e14bfd1c84eac45464903</originalsourceid><addsrcrecordid>eNpdkW1LwzAQx4Mobsy98gsUfCNINWnSJn0jyHwaTCZOfRvS9Ooy2mY27WTf3pQNUY-Du-N-_LkHhE4JvqQ0xVcrXREcRbH3AzSMMOchpoIe_soHaOzcCnsTgkWEH6MBZYLiGPMhellsq3VrKxeoooUmmMzfp7chSYNpXYBuja0DU_siNxuTd6p0wZdpl8FTV7ZmXUKw0CU01hnXY8-2VHV-go4KD8J4H0fo7f7udfIYzuYP08nNLNRUJG0INBZE5xlJAQsgea4ZJ4wxkWSMUK6KtKAQF0wnggNhWZETLRgozWKWsBTTEbre6a67rIJcQ902qpTrxlSq2UqrjPzbqc1SftiNFAkRVPQC53uBxn524FpZGaeh9EuA7ZyMEswwSdOUefTsH7qyXVP79XoqwoJHMfXUxY7S_iSugeJnGIJl_y756130GxwDhZg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2602087253</pqid></control><display><type>article</type><title>Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Czarnowska, Agata ; Kapica-Topczewska, Katarzyna ; Zajkowska, Olga ; Adamczyk-Sowa, Monika ; Kubicka-Bączyk, Katarzyna ; Niedziela, Natalia ; Warmus, Paweł ; Kalinowska-Łyszczarz, Alicja ; Kania, Karolina ; Słowik, Agnieszka ; Wnuk, Marcin ; Marona, Monika ; Nowak, Klaudia ; Bartosik-Psujek, Halina ; Lech, Beata ; Perenc, Adam ; Popiel, Małgorzata ; Kucharska-Lipowska, Marta ; Chorąży, Monika ; Tarasiuk, Joanna ; Mirończuk, Anna ; Kochanowicz, Jan ; Lasek-Bal, Anetta ; Puz, Przemysław ; Maciejowska, Katarzyna ; Wawrzyniak, Sławomir ; Niezgodzińska-Maciejek, Anna ; Pokryszko-Dragan, Anna ; Gruszka, Ewa ; Budrewicz, Sławomir ; Białek, Marta ; Zwiernik, Jacek ; Michałowska, Anna ; Nosek, Krzysztof ; Zwiernik, Beata ; Lewańczyk, Bożena ; Brola, Waldemar ; Kułakowska, Alina</creator><creatorcontrib>Czarnowska, Agata ; Kapica-Topczewska, Katarzyna ; Zajkowska, Olga ; Adamczyk-Sowa, Monika ; Kubicka-Bączyk, Katarzyna ; Niedziela, Natalia ; Warmus, Paweł ; Kalinowska-Łyszczarz, Alicja ; Kania, Karolina ; Słowik, Agnieszka ; Wnuk, Marcin ; Marona, Monika ; Nowak, Klaudia ; Bartosik-Psujek, Halina ; Lech, Beata ; Perenc, Adam ; Popiel, Małgorzata ; Kucharska-Lipowska, Marta ; Chorąży, Monika ; Tarasiuk, Joanna ; Mirończuk, Anna ; Kochanowicz, Jan ; Lasek-Bal, Anetta ; Puz, Przemysław ; Maciejowska, Katarzyna ; Wawrzyniak, Sławomir ; Niezgodzińska-Maciejek, Anna ; Pokryszko-Dragan, Anna ; Gruszka, Ewa ; Budrewicz, Sławomir ; Białek, Marta ; Zwiernik, Jacek ; Michałowska, Anna ; Nosek, Krzysztof ; Zwiernik, Beata ; Lewańczyk, Bożena ; Brola, Waldemar ; Kułakowska, Alina</creatorcontrib><description>(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection; 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm10225225</identifier><identifier>PMID: 34830507</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Antigens ; Clinical medicine ; Comorbidity ; Coronaviruses ; COVID-19 ; Demographics ; Disease ; Immunology ; Infections ; Multiple sclerosis ; Oxygen therapy ; Pain ; Pandemics ; Questionnaires ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Journal of clinical medicine, 2021-11, Vol.10 (22), p.5225</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-e3581cdb19e08e1ddc47144486b4137af9f3e5f4c687e14bfd1c84eac45464903</citedby><cites>FETCH-LOGICAL-c386t-e3581cdb19e08e1ddc47144486b4137af9f3e5f4c687e14bfd1c84eac45464903</cites><orcidid>0000-0002-7955-3454 ; 0000-0001-8378-2340 ; 0000-0001-6520-1303 ; 0000-0002-6894-9891 ; 0000-0003-0834-5727 ; 0000-0002-2860-6456</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618380/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618380/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids></links><search><creatorcontrib>Czarnowska, Agata</creatorcontrib><creatorcontrib>Kapica-Topczewska, Katarzyna</creatorcontrib><creatorcontrib>Zajkowska, Olga</creatorcontrib><creatorcontrib>Adamczyk-Sowa, Monika</creatorcontrib><creatorcontrib>Kubicka-Bączyk, Katarzyna</creatorcontrib><creatorcontrib>Niedziela, Natalia</creatorcontrib><creatorcontrib>Warmus, Paweł</creatorcontrib><creatorcontrib>Kalinowska-Łyszczarz, Alicja</creatorcontrib><creatorcontrib>Kania, Karolina</creatorcontrib><creatorcontrib>Słowik, Agnieszka</creatorcontrib><creatorcontrib>Wnuk, Marcin</creatorcontrib><creatorcontrib>Marona, Monika</creatorcontrib><creatorcontrib>Nowak, Klaudia</creatorcontrib><creatorcontrib>Bartosik-Psujek, Halina</creatorcontrib><creatorcontrib>Lech, Beata</creatorcontrib><creatorcontrib>Perenc, Adam</creatorcontrib><creatorcontrib>Popiel, Małgorzata</creatorcontrib><creatorcontrib>Kucharska-Lipowska, Marta</creatorcontrib><creatorcontrib>Chorąży, Monika</creatorcontrib><creatorcontrib>Tarasiuk, Joanna</creatorcontrib><creatorcontrib>Mirończuk, Anna</creatorcontrib><creatorcontrib>Kochanowicz, Jan</creatorcontrib><creatorcontrib>Lasek-Bal, Anetta</creatorcontrib><creatorcontrib>Puz, Przemysław</creatorcontrib><creatorcontrib>Maciejowska, Katarzyna</creatorcontrib><creatorcontrib>Wawrzyniak, Sławomir</creatorcontrib><creatorcontrib>Niezgodzińska-Maciejek, Anna</creatorcontrib><creatorcontrib>Pokryszko-Dragan, Anna</creatorcontrib><creatorcontrib>Gruszka, Ewa</creatorcontrib><creatorcontrib>Budrewicz, Sławomir</creatorcontrib><creatorcontrib>Białek, Marta</creatorcontrib><creatorcontrib>Zwiernik, Jacek</creatorcontrib><creatorcontrib>Michałowska, Anna</creatorcontrib><creatorcontrib>Nosek, Krzysztof</creatorcontrib><creatorcontrib>Zwiernik, Beata</creatorcontrib><creatorcontrib>Lewańczyk, Bożena</creatorcontrib><creatorcontrib>Brola, Waldemar</creatorcontrib><creatorcontrib>Kułakowska, Alina</creatorcontrib><title>Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland</title><title>Journal of clinical medicine</title><description>(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection; 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms.</description><subject>Antigens</subject><subject>Clinical medicine</subject><subject>Comorbidity</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Demographics</subject><subject>Disease</subject><subject>Immunology</subject><subject>Infections</subject><subject>Multiple sclerosis</subject><subject>Oxygen therapy</subject><subject>Pain</subject><subject>Pandemics</subject><subject>Questionnaires</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkW1LwzAQx4Mobsy98gsUfCNINWnSJn0jyHwaTCZOfRvS9Ooy2mY27WTf3pQNUY-Du-N-_LkHhE4JvqQ0xVcrXREcRbH3AzSMMOchpoIe_soHaOzcCnsTgkWEH6MBZYLiGPMhellsq3VrKxeoooUmmMzfp7chSYNpXYBuja0DU_siNxuTd6p0wZdpl8FTV7ZmXUKw0CU01hnXY8-2VHV-go4KD8J4H0fo7f7udfIYzuYP08nNLNRUJG0INBZE5xlJAQsgea4ZJ4wxkWSMUK6KtKAQF0wnggNhWZETLRgozWKWsBTTEbre6a67rIJcQ902qpTrxlSq2UqrjPzbqc1SftiNFAkRVPQC53uBxn524FpZGaeh9EuA7ZyMEswwSdOUefTsH7qyXVP79XoqwoJHMfXUxY7S_iSugeJnGIJl_y756130GxwDhZg</recordid><startdate>20211110</startdate><enddate>20211110</enddate><creator>Czarnowska, Agata</creator><creator>Kapica-Topczewska, Katarzyna</creator><creator>Zajkowska, Olga</creator><creator>Adamczyk-Sowa, Monika</creator><creator>Kubicka-Bączyk, Katarzyna</creator><creator>Niedziela, Natalia</creator><creator>Warmus, Paweł</creator><creator>Kalinowska-Łyszczarz, Alicja</creator><creator>Kania, Karolina</creator><creator>Słowik, Agnieszka</creator><creator>Wnuk, Marcin</creator><creator>Marona, Monika</creator><creator>Nowak, Klaudia</creator><creator>Bartosik-Psujek, Halina</creator><creator>Lech, Beata</creator><creator>Perenc, Adam</creator><creator>Popiel, Małgorzata</creator><creator>Kucharska-Lipowska, Marta</creator><creator>Chorąży, Monika</creator><creator>Tarasiuk, Joanna</creator><creator>Mirończuk, Anna</creator><creator>Kochanowicz, Jan</creator><creator>Lasek-Bal, Anetta</creator><creator>Puz, Przemysław</creator><creator>Maciejowska, Katarzyna</creator><creator>Wawrzyniak, Sławomir</creator><creator>Niezgodzińska-Maciejek, Anna</creator><creator>Pokryszko-Dragan, Anna</creator><creator>Gruszka, Ewa</creator><creator>Budrewicz, Sławomir</creator><creator>Białek, Marta</creator><creator>Zwiernik, Jacek</creator><creator>Michałowska, Anna</creator><creator>Nosek, Krzysztof</creator><creator>Zwiernik, Beata</creator><creator>Lewańczyk, Bożena</creator><creator>Brola, Waldemar</creator><creator>Kułakowska, Alina</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7955-3454</orcidid><orcidid>https://orcid.org/0000-0001-8378-2340</orcidid><orcidid>https://orcid.org/0000-0001-6520-1303</orcidid><orcidid>https://orcid.org/0000-0002-6894-9891</orcidid><orcidid>https://orcid.org/0000-0003-0834-5727</orcidid><orcidid>https://orcid.org/0000-0002-2860-6456</orcidid></search><sort><creationdate>20211110</creationdate><title>Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland</title><author>Czarnowska, Agata ; Kapica-Topczewska, Katarzyna ; Zajkowska, Olga ; Adamczyk-Sowa, Monika ; Kubicka-Bączyk, Katarzyna ; Niedziela, Natalia ; Warmus, Paweł ; Kalinowska-Łyszczarz, Alicja ; Kania, Karolina ; Słowik, Agnieszka ; Wnuk, Marcin ; Marona, Monika ; Nowak, Klaudia ; Bartosik-Psujek, Halina ; Lech, Beata ; Perenc, Adam ; Popiel, Małgorzata ; Kucharska-Lipowska, Marta ; Chorąży, Monika ; Tarasiuk, Joanna ; Mirończuk, Anna ; Kochanowicz, Jan ; Lasek-Bal, Anetta ; Puz, Przemysław ; Maciejowska, Katarzyna ; Wawrzyniak, Sławomir ; Niezgodzińska-Maciejek, Anna ; Pokryszko-Dragan, Anna ; Gruszka, Ewa ; Budrewicz, Sławomir ; Białek, Marta ; Zwiernik, Jacek ; Michałowska, Anna ; Nosek, Krzysztof ; Zwiernik, Beata ; Lewańczyk, Bożena ; Brola, Waldemar ; Kułakowska, Alina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-e3581cdb19e08e1ddc47144486b4137af9f3e5f4c687e14bfd1c84eac45464903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Clinical medicine</topic><topic>Comorbidity</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Demographics</topic><topic>Disease</topic><topic>Immunology</topic><topic>Infections</topic><topic>Multiple sclerosis</topic><topic>Oxygen therapy</topic><topic>Pain</topic><topic>Pandemics</topic><topic>Questionnaires</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Czarnowska, Agata</creatorcontrib><creatorcontrib>Kapica-Topczewska, Katarzyna</creatorcontrib><creatorcontrib>Zajkowska, Olga</creatorcontrib><creatorcontrib>Adamczyk-Sowa, Monika</creatorcontrib><creatorcontrib>Kubicka-Bączyk, Katarzyna</creatorcontrib><creatorcontrib>Niedziela, Natalia</creatorcontrib><creatorcontrib>Warmus, Paweł</creatorcontrib><creatorcontrib>Kalinowska-Łyszczarz, Alicja</creatorcontrib><creatorcontrib>Kania, Karolina</creatorcontrib><creatorcontrib>Słowik, Agnieszka</creatorcontrib><creatorcontrib>Wnuk, Marcin</creatorcontrib><creatorcontrib>Marona, Monika</creatorcontrib><creatorcontrib>Nowak, Klaudia</creatorcontrib><creatorcontrib>Bartosik-Psujek, Halina</creatorcontrib><creatorcontrib>Lech, Beata</creatorcontrib><creatorcontrib>Perenc, Adam</creatorcontrib><creatorcontrib>Popiel, Małgorzata</creatorcontrib><creatorcontrib>Kucharska-Lipowska, Marta</creatorcontrib><creatorcontrib>Chorąży, Monika</creatorcontrib><creatorcontrib>Tarasiuk, Joanna</creatorcontrib><creatorcontrib>Mirończuk, Anna</creatorcontrib><creatorcontrib>Kochanowicz, Jan</creatorcontrib><creatorcontrib>Lasek-Bal, Anetta</creatorcontrib><creatorcontrib>Puz, Przemysław</creatorcontrib><creatorcontrib>Maciejowska, Katarzyna</creatorcontrib><creatorcontrib>Wawrzyniak, Sławomir</creatorcontrib><creatorcontrib>Niezgodzińska-Maciejek, Anna</creatorcontrib><creatorcontrib>Pokryszko-Dragan, Anna</creatorcontrib><creatorcontrib>Gruszka, Ewa</creatorcontrib><creatorcontrib>Budrewicz, Sławomir</creatorcontrib><creatorcontrib>Białek, Marta</creatorcontrib><creatorcontrib>Zwiernik, Jacek</creatorcontrib><creatorcontrib>Michałowska, Anna</creatorcontrib><creatorcontrib>Nosek, Krzysztof</creatorcontrib><creatorcontrib>Zwiernik, Beata</creatorcontrib><creatorcontrib>Lewańczyk, Bożena</creatorcontrib><creatorcontrib>Brola, Waldemar</creatorcontrib><creatorcontrib>Kułakowska, Alina</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Czarnowska, Agata</au><au>Kapica-Topczewska, Katarzyna</au><au>Zajkowska, Olga</au><au>Adamczyk-Sowa, Monika</au><au>Kubicka-Bączyk, Katarzyna</au><au>Niedziela, Natalia</au><au>Warmus, Paweł</au><au>Kalinowska-Łyszczarz, Alicja</au><au>Kania, Karolina</au><au>Słowik, Agnieszka</au><au>Wnuk, Marcin</au><au>Marona, Monika</au><au>Nowak, Klaudia</au><au>Bartosik-Psujek, Halina</au><au>Lech, Beata</au><au>Perenc, Adam</au><au>Popiel, Małgorzata</au><au>Kucharska-Lipowska, Marta</au><au>Chorąży, Monika</au><au>Tarasiuk, Joanna</au><au>Mirończuk, Anna</au><au>Kochanowicz, Jan</au><au>Lasek-Bal, Anetta</au><au>Puz, Przemysław</au><au>Maciejowska, Katarzyna</au><au>Wawrzyniak, Sławomir</au><au>Niezgodzińska-Maciejek, Anna</au><au>Pokryszko-Dragan, Anna</au><au>Gruszka, Ewa</au><au>Budrewicz, Sławomir</au><au>Białek, Marta</au><au>Zwiernik, Jacek</au><au>Michałowska, Anna</au><au>Nosek, Krzysztof</au><au>Zwiernik, Beata</au><au>Lewańczyk, Bożena</au><au>Brola, Waldemar</au><au>Kułakowska, Alina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland</atitle><jtitle>Journal of clinical medicine</jtitle><date>2021-11-10</date><risdate>2021</risdate><volume>10</volume><issue>22</issue><spage>5225</spage><pages>5225-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection; 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34830507</pmid><doi>10.3390/jcm10225225</doi><orcidid>https://orcid.org/0000-0002-7955-3454</orcidid><orcidid>https://orcid.org/0000-0001-8378-2340</orcidid><orcidid>https://orcid.org/0000-0001-6520-1303</orcidid><orcidid>https://orcid.org/0000-0002-6894-9891</orcidid><orcidid>https://orcid.org/0000-0003-0834-5727</orcidid><orcidid>https://orcid.org/0000-0002-2860-6456</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2021-11, Vol.10 (22), p.5225 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8618380 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central; EZB Electronic Journals Library; PubMed Central Open Access |
| subjects | Antigens Clinical medicine Comorbidity Coronaviruses COVID-19 Demographics Disease Immunology Infections Multiple sclerosis Oxygen therapy Pain Pandemics Questionnaires Severe acute respiratory syndrome coronavirus 2 |
| title | Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A54%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Symptoms%20after%20COVID-19%20Infection%20in%20Individuals%20with%20Multiple%20Sclerosis%20in%20Poland&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Czarnowska,%20Agata&rft.date=2021-11-10&rft.volume=10&rft.issue=22&rft.spage=5225&rft.pages=5225-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm10225225&rft_dat=%3Cproquest_pubme%3E2604019994%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2602087253&rft_id=info:pmid/34830507&rfr_iscdi=true |